Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

VSL#3 TM & Pediatric Non-Alcoholic Fatty Liver Disease (Child-NAFLD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

NCT01650025
demonstrated that a four-month regimen of VSL#3 significantly enhances the condition of Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) in children. The observed improvement may be attributed to the increase in Glucagon Like Peptide 1 (GLP-1) levels induced by VSL#3 TM (1)

(1) Alisi et al. 2014 Aliment. Pharmacol. Ther. 39: 1276–1285

see also:
[Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated …

Randomised clinical trial: The beneﬁcial effects of VSL#3 in obese children with non-alcoholic steatohepatitis
Alisi et al. 2014 Aliment. Pharmacol. Ther. 39: 1276–1285

7/1/2026